New Haven, CT – According to filings with the U.S. Securities and Exchange Commission, CoRISMA MCS Systems is raising $14,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Michael Theran played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CoRISMA MCS Systems
CoRISMA Cardiovascular is a medical device company developing a heart failure system to treat patients suffering from advanced heart failure. CoRISMA, spun out of the Bonde Artificial Heart Lab at Yale University, is positioned to disrupt the existing market. CoRISMA is a fully implanted transcatheter device that is wirelessly powered with our world renowned energy transmission technology. Our team is devoted to developing this transformative device for the countless advanced heart failure patients and their clinicians seeking alternatives to existing treatments. We are further motivated to dramatically reduce the tremendous economic burden each country faces treating heart failure.

To learn more about CoRISMA MCS Systems, visit http://www.corismacv.com/

Contact:
Michael Theran, President and Chief Executive Officer
203-506-5025
https://www.linkedin.com/in/mike-theran/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved